Effect of Minoxidil Solution Iontophoresis on Androgenic Alopecia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Minoxidil solution iontophoresis, saline solution iontophoresis.
- Who it may be relevant to
- Registry conditions: Alopecia. Basic parameters: 18 years — 65 years · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The aim of the study is to evaluate the therapeutic efficiency of minoxidil solution iontophoresis on Androgenic Alopecia.
Detailed description
Hair is an important component of identity and self-image. Hair loss can lead to a variety of psychological difficulties and have a negative impact on quality of life (QoL). Loss of self-confidence lowered self-esteem, and heightened self-consciousness are common responses to hair loss, particularly for women. People with alopecia are more likely to develop depression and anxiety.
Some studies have proposed iontophoresis and ultrasound as energetic drug delivery methods to favor topical therapy of alopecia. Iontophoresis is a non-invasive technique that applies a small electric current (of no more than 0.5 mA/cm2) on the skin's surface to increase and control drug delivery. The technique is widely studied to stimulate the skin penetration and permeation of hydrophilic drugs, which would not be absorbed by the skin when passively applied. The transport of drugs through the skin as a result of the electric current is driven by two different mechanisms, ie, electromigration in the case of charged drugs and electroosmosis in the case of neutral drugs.
Furthermore the need of this study is developed from the lack in quantitative knowledge and information in published studies which investigate effect of minoxidil solution iontophoresis on Androgenic alopecia.
Interventions
- Other Minoxidil solution iontophoresis
The half of the scalp of the participants will be treated with 5% minoxidil solution through Iontophoresis that will be applied at small low voltage (typically 10 V or less) continuous constant current (typically 0.5 mA/cm2 or less) to push a charged drug into skin or other tissue, twice daily at home. - Other saline solution iontophoresis
The other half of the scalp of the participants will be treated with placebo saline solution ( control) with the current application.
Primary outcome measures
- Change in the number of hair follicles [Time frame: 12 weeks]
Secondary outcome measures (1)
- Change of hair thickness [Time frame: 12 weeks]
Eligibility criteria
Inclusion criteria
- Twenty-five adult aged 18-65 with diagnosed androgenic alopecia.
- They diagnosed as Androgenic alopeacia by their physicians and referred for physical therapy management.
- Medically and psychologically stable patients.
Exclusion criteria
- History of hypersensitivity to minoxidil solution or Intophoresis.
- Scalp infection
- Concurrent hair loss treatments.
- Patients who suffer from hypertrophic and/or keloidal scars and a skin condition in the area of Androgenic alopecia that would interfere with study procedures.
- plaque psoriasis, tattoo, birthmark, facial hair.
- Patients with medical red flags as severe psychiatric disorder or cognitive deficits.
- Medically unstable and uncooperative patients.
- Immunocompromised status.
- History of skin cancer.
- Recurrent herpes viral infection.
- Pregnancy or breastfeeding status.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Mahmoud Ibrahim Mohamed — Zagazig
Identifiers
NCT: NCT07056933 · 012/005693